Search Results - "Myocardial Infarction/epidemiology [MeSH]"

  • Showing 1 - 17 results of 17
Refine Results
  1. 1
  2. 2

    Source: Clin Res Cardiol
    Clinical research in cardiology, 113(7):1006-1016

    Subject Terms: Male, Ticagrelor, Time Factors, Myocardial Infarction, Percutaneous Coronary Intervention/methods [MeSH], Purinergic P2Y Receptor Antagonists/administration, Aged [MeSH], No-Reflow Phenomenon/epidemiology [MeSH], Prasugrel Hydrochloride/adverse effects [MeSH], Prasugrel Hydrochloride/administration, Risk Factors [MeSH], Platelet Aggregation Inhibitors/therapeutic use [MeSH], Prognosis, Acute myocardial infarction, No-Reflow Phenomenon/etiology [MeSH], Platelet Aggregation Inhibitors/administration, Male [MeSH], Ticagrelor/therapeutic use [MeSH], Drug-Eluting Stents [MeSH], Purinergic P2Y Receptor Antagonists/therapeutic use [MeSH], Coronary no-reflow, Purinergic P2Y Receptor Antagonists/adverse effects [MeSH], Female [MeSH], Follow-Up Studies [MeSH], Prasugrel Hydrochloride/therapeutic use [MeSH], Humans [MeSH], Ticagrelor/administration, Treatment Outcome [MeSH], Ticagrelor/adverse effects [MeSH], Incidence [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Time Factors [MeSH], Percutaneous Coronary Intervention/adverse effects [MeSH], Myocardial Infarction/epidemiology [MeSH], Original Paper, Platelet Aggregation Inhibitors/adverse effects [MeSH], Percutaneous coronary intervention, 03 medical and health sciences, Percutaneous Coronary Intervention, 0302 clinical medicine, Risk Factors, Humans, Aged, Retrospective Studies, Incidence, Drug-Eluting Stents, Middle Aged, Medical and Health Sciences, ddc, 3. Good health, Treatment Outcome, Purinergic P2Y Receptor Antagonists, No-Reflow Phenomenon, Female, Prasugrel Hydrochloride, Platelet Aggregation Inhibitors, Follow-Up Studies

    File Description: application/pdf

  3. 3
  4. 4

    Source: Cardiovasc Diabetol
    Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-7 (2024)

  5. 5
  6. 6
  7. 7
  8. 8

    Source: Clin Res Cardiol
    Clin. Res. Cardiol. 110, 1564-1573 (2021)

    File Description: application/pdf

  9. 9

    Source: Eur J Health Econ

    Subject Terms: Male, Survival, Adrenergic beta-Antagonists, Myocardial Infarction, Angiotensin-Converting Enzyme Inhibitors, Coronary Artery Disease, Kaplan-Meier Estimate, AMI, DMP CAD, Insurance Claim Review, 03 medical and health sciences, 0302 clinical medicine, Germany, Health care expenditures, Humans, Guideline-based medication, Propensity Score, H51, Proportional Hazards Models, Assessment of Medication Adherence, ddc:610, Original Paper, I18, I11, 4. Education, Antibodies, Monoclonal, Disease Management, 3. Good health, Drug Combinations, Practice Guidelines as Topic, Medication Adherence/statistics, Drug Combinations [MeSH], Coronary Artery Disease/economics [MeSH], Practice Guidelines as Topic [MeSH], Health Expenditures/statistics, Disease Management [MeSH], Germany/epidemiology [MeSH], Platelet Aggregation Inhibitors/administration, Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration, Proportional Hazards Models [MeSH], Male [MeSH], Adrenergic beta-Antagonists/administration, Propensity Score [MeSH], Angiotensin-Converting Enzyme Inhibitors/administration, Female [MeSH], Coronary Artery Disease/mortality [MeSH], Insurance Claim Review [MeSH], Kaplan-Meier Estimate [MeSH], Humans [MeSH], Coronary Artery Disease/drug therapy [MeSH], Antibodies, Monoclonal [MeSH], Coronary Artery Disease/epidemiology [MeSH], Myocardial Infarction/epidemiology [MeSH], Female, Health Expenditures, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Platelet Aggregation Inhibitors

  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17